News

FDA’s new app provides info on drug shortages


 

An iPhone (left) and

a Nokia smart phone

Photo by Halvard Lundgaard

The US Food and Drug Administration (FDA) has launched the agency’s first mobile application (app) designed to speed public access to information on drug shortages.

The app provides details regarding current drug shortages, resolved shortages, and discontinued drug products.

It works just like the FDA’s drug shortages website. App users can search for a drug by its generic name or active ingredient, or they can browse by therapeutic category.

The app can also be used to report a suspected drug shortage or supply issue to the FDA.

The app is available for free download via iTunes (for Apple devices) and the Google Play store (for Android devices). It can be found by searching “FDA Drug Shortages.”

The FDA developed the app to improve access to information about drug shortages, as part of the agency’s efforts outlined in the Strategic Plan for Preventing and Mitigating Drug Shortages.

“The FDA understands that healthcare professionals and pharmacists need real-time information about drug shortages to make treatment decisions,” said Valerie Jensen, associate director of the Drug Shortage Staff in the FDA’s Center for Drug Evaluation and Research.

“The new mobile app is an innovative tool that will offer easier and faster access to important drug shortage information.”

Recommended Reading

Too many blood tests can lead to anemia, transfusions
MDedge Hematology and Oncology
FDA approves first HDAC inhibitor for MM
MDedge Hematology and Oncology
EC expands indication for lenalidomide in MM
MDedge Hematology and Oncology
Generic enoxaparin launched in US
MDedge Hematology and Oncology
FDA approves drug for newly diagnosed MM
MDedge Hematology and Oncology
FDA issues documents on drug compounding
MDedge Hematology and Oncology
NICE rejects pomalidomide as MM treatment
MDedge Hematology and Oncology
Anticoagulant now available in US pharmacies
MDedge Hematology and Oncology
EC approves bortezomib for MCL
MDedge Hematology and Oncology
Though costly, blood cancer drugs appear cost-effective
MDedge Hematology and Oncology